New combo therapy aims to boost remission in tough rectal cancer
NCT ID NCT07527520
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new approach for high-risk locally advanced rectal cancer. It combines a shorter course of radiation with chemotherapy (capecitabine and oxaliplatin) and an immunotherapy drug (serplulimab). The study will compare this combo to standard chemoradiation in 165 patients to see if it leads to higher complete remission rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Moderately hypofractionated radiotherapy, capecitabine, oxaliplatin, and serplulimab
- What this could lead to
- If successful, this could offer a more effective and shorter treatment option for patients with high-risk locally advanced rectal cancer, potentially increasing the chance of complete remission.
- What could go wrong
- This is a phase 2 trial with only 165 participants, so results are preliminary. The combination of treatments may increase side effects, and it is not yet known if it will improve long-term survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATELY HYPOFRACTIONATED RADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan hosptial, Fudan University
Shanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Rearranging the treatment timeline: could a new sequence of chemo and radiation spare rectal cancer patients from major surgery?
- Rectal cancer: could a 'Watch and Wait' strategy spare patients from major surgery?
- Dye-Free laser imaging could replace standard dye in colorectal surgery
- Could your own gut bacteria restore bowel control after cancer surgery?
- New drug combo aims to eliminate rectal tumors before surgery
- Giving cancer patients a say in genetic results may boost knowledge and satisfaction